NovoCure/$NVCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NovoCure
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Ticker
$NVCR
Sector
Primary listing
Employees
1,488
Headquarters
Baar, Switzerland
Website
NovoCure Metrics
BasicAdvanced
$1.6B
-
-$1.56
0.72
-
Price and volume
Market cap
$1.6B
Beta
0.72
52-week high
$34.13
52-week low
$10.87
Average daily volume
1.7M
Financial strength
Current ratio
1.445
Quick ratio
1.388
Long term debt to equity
40.196
Total debt to equity
200.392
Interest coverage (TTM)
-12.27%
Profitability
EBITDA (TTM)
-158.863
Gross margin (TTM)
76.54%
Net profit margin (TTM)
-27.13%
Operating margin (TTM)
-26.95%
Effective tax rate (TTM)
-20.33%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-8.64%
Return on equity (TTM)
-48.07%
Valuation
Price to revenue (TTM)
2.549
Price to book
4.69
Price to tangible book (TTM)
4.69
Price to free cash flow (TTM)
-19.977
Free cash flow yield (TTM)
-5.01%
Free cash flow per share (TTM)
-0.734
Growth
Revenue change (TTM)
14.58%
Earnings per share change (TTM)
-1.15%
3-year revenue growth (CAGR)
4.94%
10-year revenue growth (CAGR)
41.25%
3-year earnings per share growth (CAGR)
33.52%
10-year earnings per share growth (CAGR)
-14.37%
What the Analysts think about NovoCure
Analyst ratings (Buy, Hold, Sell) for NovoCure stock.
Bulls say / Bears say
NovoCure’s Q2 2025 net revenues rose 6% year-over-year to $158.8 million, surpassing the $150.4 million reported in Q2 2024 and beating analyst expectations by $4.6 million, fueled by strong patient growth.
Active patients on TTFields therapy increased 9.3% year-over-year to 4,331 in Q2 2025, highlighting solid uptake of both Optune Gio and the recently launched Optune Lua indications.
Optune Lua generated $2.4 million in Q2 2025 revenue—with $1.1 million from NSCLC and $1.3 million from MPM—demonstrating early commercial success in non-glioblastoma indications.
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
NovoCure Financial Performance
Revenues and expenses
NovoCure Earnings Performance
Company profitability
NovoCure News
AllArticlesVideos
Novocure to Report Third Quarter 2025 Financial Results
Business Wire4 days ago
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
Business Wire5 days ago
Novocure Announces Upcoming Investor Events
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NovoCure stock?
NovoCure (NVCR) has a market cap of $1.6B as of October 05, 2025.
What is the P/E ratio for NovoCure stock?
The price to earnings (P/E) ratio for NovoCure (NVCR) stock is 0 as of October 05, 2025.
Does NovoCure stock pay dividends?
No, NovoCure (NVCR) stock does not pay dividends to its shareholders as of October 05, 2025.
When is the next NovoCure dividend payment date?
NovoCure (NVCR) stock does not pay dividends to its shareholders.
What is the beta indicator for NovoCure?
NovoCure (NVCR) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.